Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | SDHB | P21912 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5694238 | 0.84 | CHRNA7 (0.44) | HPGDTP53LMNACYP1A2KDM4E | |
| SCHEMBL37563 | 0.81 | KMT2A (0.42) | RAB9APOLBMEN1KMT2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL11060859 | 0.79 | KMT2A (0.41) | RAB9APOLBMEN1KMT2ACYP1A2 | |
| Bromide SCHEMBL28947954 | 0.79 | KMT2A (0.41) | RAB9APOLBMEN1KMT2ACYP1A2 | |
| SCHEMBL4063789 | 0.77 | AKT1 (0.43) | RAB9ALMNAPOLBMEN1KMT2A | |
| Succinic Acid SCHEMBL29123713 | 0.76 | FFAR1 (0.43) | HPGDTP53RAB9ALMNAHSD17B10 | |
| Biphenyl SCHEMBL1050411 | 0.75 | PTPN1 (0.58) | PTPN1MEN1MAPK1HTTKMT2A | |
| Trifluoromethanesulfonic Acid SCHEMBL2391326 | 0.74 | CYP2A6 (0.47) | PTPN1RAB9ALMNAPOLBCYP1A2 | |
| SCHEMBL6197482 | 0.73 | LMNA (0.41) | HPGDLMNAPOLBMEN1HTT | |
| Biphenyl SCHEMBL5410059 | 0.73 | PTPN1 (0.56) | PTPN1MEN1MAPK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | claimed |
| EP-4658396-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4547683-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240343746-A1 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | BANK OF AMERICA, N.A. | 2024-10-17 | — | — | US | disclosed |
| WO-2024163644-A1 | BELT REACTOR MANUFACTURING PROCESS FOR OLIGOMER SYNTHESIS | Arrowhead Pharmaceuticals, Inc. (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2024006999-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4271696-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343746-A1 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | RNGTT, TYMP, DCTPP1 | PTPN1 644/4885HPGD 2096/4885TP53 1073/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | PTPN1 4638/4885HPGD 1744/4885TP53 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.